Small-molecule inhibitors of the human epidermal receptor family.
作者： Corey A Carter , Ronan J Kelly , Giuseppe Giaccone
DOI: 10.1517/13543780903373343
关键词:
摘要: Background: Small molecule inhibitors of human epidermal receptors (HER) have become an integral part the armamentarium available to medical oncologist in treatment solid tumor malignancies. At present, there are two small-molecule (erlotinib and lapatinib) approved by FDA USA, a third inhibitor, gefitinib, is other countries. Objective: To summarize current standards care for these new agents tumors, discuss ongoing clinical trials; review known mechanisms action as well both predictive markers response likely resistance. Methods: We reviewed key presentations recent publications on targeting HER family tumors. Conclusions: Recent data highlighted importance mutations amplifications within family. Amplification HER2 often translates into responses anti-HER2 therapy. Mutat...
elsevier.com
informahealthcare.com参考文章(103)
Ronit Pinkas-Kramarski, Iris Alroy, Yosef Yarden, ErbB receptors and EGF-like ligands: cell lineage determination and oncogenesis through combinatorial signaling. Journal of Mammary Gland Biology and Neoplasia. ,vol. 2, pp. 97- 107 ,(1997) , 10.1023/A:1026343528967
Christopher J Barnes, Rakesh Kumar, Epidermal growth factor receptor family tyrosine kinases as signal integrators and therapeutic targets Cancer and Metastasis Reviews. ,vol. 22, pp. 301- 307 ,(2003) , 10.1023/A:1023726827771
Vincent A. Pollack, Catherine DiOrio, April Theleman, Elsa G. Barbacci, Leslie R. Pustilnik, Mark Neveu, Mikel P. Moyer, Kenneth K. Iwata, Lee Arnold, Michael J. Morin, James D. Moyer, Bruce Boman, Penny Miller, Ann Cunningham, Margaret M. Reynolds, Don Sloan, Jonathan Doty, Induction of Apoptosis and Cell Cycle Arrest by CP-358,774, an Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinase Cancer Research. ,vol. 57, pp. 4838- 4848 ,(1997)
Amanda H. McCann, Peter A. Dervan, Desmond N. Carney, Brendan M. J. Tobin, Myra O'Regan, Mary B. Codd, William J. Gullick, Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Research. ,vol. 51, pp. 3296- 3303 ,(1991)
M F Press, L Bernstein, P A Thomas, L F Meisner, J Y Zhou, Y Ma, G Hung, R A Robinson, C Harris, A El-Naggar, D J Slamon, R N Phillips, J S Ross, S R Wolman, K J Flom, HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. Journal of Clinical Oncology. ,vol. 15, pp. 2894- 2904 ,(1997) , 10.1200/JCO.1997.15.8.2894
S. E. Rivkin, C. Muller, D. Iriarte, J. Arthur, A. Canoy, H. Reid, Phase I/II lapatinib plus carboplatin and paclitaxel in stage III or IV relapsed ovarian cancer patients Journal of Clinical Oncology. ,vol. 26, pp. 5556- 5556 ,(2008) , 10.1200/JCO.2008.26.15_SUPPL.5556
Takuro Wada, Xiaolan Qian, Mark I. Greene, Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function Cell. ,vol. 61, pp. 1339- 1347 ,(1990) , 10.1016/0092-8674(90)90697-D
Sreenath V. Sharma, Daphne W. Bell, Jeffrey Settleman, Daniel A. Haber, Epidermal growth factor receptor mutations in lung cancer Nature Reviews Cancer. ,vol. 7, pp. 169- 181 ,(2007) , 10.1038/NRC2088
Teemu T. Junttila, Robert W. Akita, Kathryn Parsons, Carter Fields, Gail D. Lewis Phillips, Lori S. Friedman, Deepak Sampath, Mark X. Sliwkowski, Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941 Cancer Cell. ,vol. 15, pp. 429- 440 ,(2009) , 10.1016/J.CCR.2009.03.020
Hidefumi Sasaki, Katsuhiko Endo, Minoru Takada, Masaaki Kawahara, Naoto Kitahara, Hisaichi Tanaka, Meinoshin Okumura, Akihide Matsumura, Keiji Iuchi, Tomoya Kawaguchi, Osamu Kawano, Haruhiro Yukiue, Tomoki Yokoyama, Motoki Yano, Yoshitaka Fujii, EGFR exon 20 insertion mutation in Japanese lung cancer Lung Cancer. ,vol. 58, pp. 324- 328 ,(2007) , 10.1016/J.LUNGCAN.2007.06.024